Search - tctmd.com

Displaying 1 - 20 of 37

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations

News Conference News TCT 2025

AI-ECG Finds STEMI Faster, Cuts False-Positive Cath Lab Activations

October 31, 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI

News Conference News TCT 2024

DRAMI: No Clear Winner for Distal vs Traditional Radial Access in STEMI

October 29, 2024

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

News Conference News TCT 2023

OCT, IVUS Both Seem to Be Good Options for Complex Coronary Lesions

October 23, 2023

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

News Conference News TCT 2022

Calcified Nodules Signal Worst Outcome Among OCT-Defined ACS Causes

September 22, 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

News Conference News TCT 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

November 04, 2021

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

News Conference News TCT 2020

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

October 22, 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

October 21, 2020

IVUS-Guided PCI Gains Support With Longer-Term ULTIMATE Results

News Conference News TCT 2020

IVUS-Guided PCI Gains Support With Longer-Term ULTIMATE Results

October 15, 2020

Delays, Deaths, and More Cardiogenic Shock Among ACS Patients With COVID-19

News Conference News TCT 2020

Delays, Deaths, and More Cardiogenic Shock Among ACS Patients With COVID-19

October 14, 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

News Conference News TCT 2020

Ticagrelor Monotherapy Following 3-Month DAPT Cuts Post-PCI Bleeding After STEMI

October 14, 2020

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

October 03, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

September 30, 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

News Conference News TCT 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

September 28, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.